-
Something wrong with this record ?
Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent Effect on DNA interactions, DNA adduct recognition and repair
H. Kostrhunova, J. Malina, AJ. Pickard, J. Stepankova, M. Vojtiskova, J. Kasparkova, T. Muchova, ML. Rohlfing, U. Bierbach, V. Brabec
Language English Country United States
Document type Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
21806015
DOI
10.1021/mp200309x
Knihovny.cz E-resources
- MeSH
- DNA Adducts chemistry MeSH
- Acridines chemistry metabolism pharmacology MeSH
- Amidines chemistry metabolism pharmacology MeSH
- Antineoplastic Agents chemistry metabolism pharmacology MeSH
- DNA, B-Form chemistry metabolism MeSH
- Cisplatin analogs & derivatives chemistry metabolism pharmacology MeSH
- DNA chemistry metabolism MeSH
- Transcription, Genetic drug effects MeSH
- HeLa Cells MeSH
- Intercalating Agents chemistry metabolism pharmacology MeSH
- Kinetics MeSH
- Nucleic Acid Conformation drug effects MeSH
- Humans MeSH
- DNA Repair drug effects MeSH
- Organoplatinum Compounds chemistry metabolism pharmacology MeSH
- Protein Isoforms metabolism MeSH
- HMGB1 Protein metabolism MeSH
- Drug Design MeSH
- Thiourea chemistry metabolism pharmacology MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Research Support, N.I.H., Extramural MeSH
- Comparative Study MeSH
A combination of biophysical, biochemical, and computational techniques was used to delineate mechanistic differences between the platinum-acridine hybrid agent [PtCl(en)(L)](NO(3))(2) (complex 1, en = ethane-1,2-diamine, L = 1-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea) and a considerably more potent second-generation analogue containing L' = N-[2-(acridin-9-ylamino)ethyl]-N-methylpropionamidine (complex 2). Calculations at the density functional theory level provide a rationale for the binding preference of both complexes for guanine-N7 and the relatively high level of adenine adducts observed for compound 1. A significant rate enhancement is observed for binding of the amidine-based complex 2 with DNA compared with the thiourea-based prototype 1. Studies conducted with chemical probes and on the bending and unwinding of model duplex DNA suggest that adducts of complex 2 perturb B-form DNA more severely than complex 1, however, without denaturing the double strand and significantly less than cisplatin. Circular and linear dichroism spectroscopies and viscosity measurements suggest that subtle differences exist between the intercalation modes and adduct geometries of the two complexes. The adducts formed by complex 2 most efficiently inhibit transcription of the damaged DNA by RNA polymerase II. Not only do complexes 1 and 2 cause less distortion to DNA than cisplatin, they also do not compromise the thermodynamic stability of the modified duplex. This leads to a decreased or negligible affinity of HMG domain proteins for the adducts formed by either Pt-acridine complex. In a DNA repair synthesis assay the lesions formed by complex 2 were repaired less efficiently than those formed by complex 1. These significant differences in DNA adduct formation, structure, and recognition between the two acridine complexes and cisplatin help to elucidate why compound 2 is highly active in cisplatin-resistant, repair proficient cancer cell lines.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12022483
- 003
- CZ-PrNML
- 005
- 20130324220219.0
- 007
- ta
- 008
- 120806e20110817xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1021/mp200309x $2 doi
- 035 __
- $a (PubMed)21806015
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kostrhunová, Hana. $7 _AN047101 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, vvi Kralovopolska 135, CZ-61265 Brno, Czech Republic.
- 245 10
- $a Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent Effect on DNA interactions, DNA adduct recognition and repair / $c H. Kostrhunova, J. Malina, AJ. Pickard, J. Stepankova, M. Vojtiskova, J. Kasparkova, T. Muchova, ML. Rohlfing, U. Bierbach, V. Brabec
- 520 9_
- $a A combination of biophysical, biochemical, and computational techniques was used to delineate mechanistic differences between the platinum-acridine hybrid agent [PtCl(en)(L)](NO(3))(2) (complex 1, en = ethane-1,2-diamine, L = 1-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea) and a considerably more potent second-generation analogue containing L' = N-[2-(acridin-9-ylamino)ethyl]-N-methylpropionamidine (complex 2). Calculations at the density functional theory level provide a rationale for the binding preference of both complexes for guanine-N7 and the relatively high level of adenine adducts observed for compound 1. A significant rate enhancement is observed for binding of the amidine-based complex 2 with DNA compared with the thiourea-based prototype 1. Studies conducted with chemical probes and on the bending and unwinding of model duplex DNA suggest that adducts of complex 2 perturb B-form DNA more severely than complex 1, however, without denaturing the double strand and significantly less than cisplatin. Circular and linear dichroism spectroscopies and viscosity measurements suggest that subtle differences exist between the intercalation modes and adduct geometries of the two complexes. The adducts formed by complex 2 most efficiently inhibit transcription of the damaged DNA by RNA polymerase II. Not only do complexes 1 and 2 cause less distortion to DNA than cisplatin, they also do not compromise the thermodynamic stability of the modified duplex. This leads to a decreased or negligible affinity of HMG domain proteins for the adducts formed by either Pt-acridine complex. In a DNA repair synthesis assay the lesions formed by complex 2 were repaired less efficiently than those formed by complex 1. These significant differences in DNA adduct formation, structure, and recognition between the two acridine complexes and cisplatin help to elucidate why compound 2 is highly active in cisplatin-resistant, repair proficient cancer cell lines.
- 650 _2
- $a akridiny $x chemie $x metabolismus $x farmakologie $7 D000166
- 650 _2
- $a amidiny $x chemie $x metabolismus $x farmakologie $7 D000578
- 650 _2
- $a antitumorózní látky $x chemie $x metabolismus $x farmakologie $7 D000970
- 650 _2
- $a cisplatina $x analogy a deriváty $x chemie $x metabolismus $x farmakologie $7 D002945
- 650 _2
- $a DNA $x chemie $x metabolismus $7 D004247
- 650 _2
- $a adukty DNA $x chemie $7 D018736
- 650 _2
- $a oprava DNA $x účinky léků $7 D004260
- 650 _2
- $a B-DNA $x chemie $x metabolismus $7 D059371
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a protein HMGB1 $x metabolismus $7 D024243
- 650 _2
- $a HeLa buňky $7 D006367
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interkalátory $x chemie $x metabolismus $x farmakologie $7 D007364
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a konformace nukleové kyseliny $x účinky léků $7 D009690
- 650 _2
- $a organoplatinové sloučeniny $x chemie $x metabolismus $x farmakologie $7 D009944
- 650 _2
- $a protein - isoformy $x metabolismus $7 D020033
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a thiomočovina $x chemie $x metabolismus $x farmakologie $7 D013890
- 650 _2
- $a genetická transkripce $x účinky léků $7 D014158
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Malina, Jaroslav
- 700 1_
- $a Pickard, Amanda J
- 700 1_
- $a Štěpánková, Jana
- 700 1_
- $a Vojtiskova, Marie
- 700 1_
- $a Kašpárková, Jana, $d 1969- $7 xx0068609
- 700 1_
- $a Muchova, Tereza
- 700 1_
- $a Rohlfing, Matthew L
- 700 1_
- $a Bierbach, Ulrich
- 700 1_
- $a Brabec, Viktor, $d 1944- $7 jo20010087133
- 773 0_
- $w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 8, č. 5 (20110817), s. 1941-54
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21806015 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120806 $b ABA008
- 991 __
- $a 20130324220450 $b ABA008
- 999 __
- $a ok $b bmc $g 944396 $s 779780
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 8 $c 5 $d 1941-54 $e 20110817 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
- LZP __
- $a Pubmed-20120806/12/01